HLA class I-presented Heat Shock Protein 70-derived peptide (HSP70-pMHC)

The HLA class I-presented Heat Shock Protein 70-derived peptide is a tumor-associated antigen (TAA) complex formed when fragments of the Heat Shock Protein 70 (HSP70) family are processed and displayed on the cell surface by Human Leukocyte Antigen (HLA) class I molecules (Ciocca & Calderwood, 2005). HSP70 proteins, such as HSPA1A, function as molecular chaperones and are frequently overexpressed in a wide range of cancers, where they contribute to protein folding, anti-apoptotic signaling, and therapy resistance (Shevtsov & Multhoff, 2016). In the context of the immune system, these peptides serve as signals that a cell is stressed or malignant. Therapeutic interventions, primarily peptide vaccines, aim to stimulate the expansion of CD8+ cytotoxic T lymphocytes (CTLs) that specifically recognize these HSP70-pMHC complexes (Tamura et al., 2011). By enhancing the immune system's ability to identify and destroy cells presenting these markers, researchers hope to treat various cancers, including glioblastoma and myeloid leukemias (Izumoto et al., 2013). These vaccines are often restricted to specific HLA alleles, such as HLA-A*24:02 or HLA-A*02:01, requiring patient screening for efficacy. Clinical trials have demonstrated that these vaccines can induce specific T-cell responses and, in some cases, improve progression-free survival in patients with recurrent tumors (Izumoto et al., 2013). However, because HSP70 is a conserved self-protein, therapeutic development must carefully balance potent anti-tumor activity with the risk of inducing autoimmune responses against healthy tissues.

Other names

HSP70 peptide-HLA complexHSPA1A-derived peptide-MHC complexTumor-associated HSP70 peptideHSP70-derived tumor antigen

Active immunotherapy via induction of peptide-specific CD8+ cytotoxic T lymphocytes (CTLs) that recognize the peptide-HLA complex on tumor cells, leading to targeted cell lysis.